- 8.1.2025
- News
Combat Cocktail: How America Overmedicates Veterans
A new Wall Street Journal report reveals the VA is prescribing risky drug combinations to hundreds of thousands of veterans with PTSD—despite known risks and internal warnings. The article underscores the urgent need for safer, more effective treatments like those VETS supports through research, advocacy, and access to psychedelic-assisted therapies.

- 8.1.2025
- Blog
Freedom to Heal: What It Means And Why We’re Fighting For It
At VETS, we believe that healing is a right, not a privilege. That’s what we mean by Freedom to Heal. It’s not just a phrase. It’s a promise. And it’s the driving force behind everything we do.
- 7.25.2025
- News
Ibogaine: The Fight of a Lifetime
“Ibogaine: The Fight of a Lifetime” is a Fox Nation news segment highlighting the experiences of Special Operations veterans pursuing psychedelic-assisted therapy to address traumatic brain injury and PTSD.
- 7.23.2025
- News
Advocates want NC legislature to consider rules around psychedelics for PTSD treatment
Advocates in North Carolina are urging lawmakers to support Senate Bill 568, which would create a task force to explore safe, regulated access to psychedelic-assisted therapy for PTSD—especially for veterans. While not legalizing psychedelics, the bill aims to prepare the state for future FDA approval through infrastructure planning and veteran-focused care.
- 7.16.2025
- News
RFK Jr. and other Trump officials embrace psychedelics after FDA setback
RFK Jr. and former Trump officials are backing psychedelic therapies like MDMA and ibogaine, pushing for FDA approval amid growing bipartisan interest. The article highlights veteran voices, including VETS' Marcus Capone, advocating for access despite safety concerns.

- 7.8.2025
- Blog
A New Hope for Healing: Psilocybin Clinical Trial Now Open to Veterans
Thanks to the recent passage of SB5263, Washington State is developing a robust legal framework for Washington residents over the age of 21 to access psilocybin services. With it comes a clinical trial designed specifically for U.S. veterans.
- 7.2.2025
- News
Advocate reacts to Texas governor signing psychedelic research bill into law
An advocate featured by KXAN celebrates Texas’s new legislation as a turning point—allocating $50 million in public funding for ibogaine clinical trials to address PTSD, addiction, and brain injury. She highlights the significance of this support for veterans and first responders.
- 7.2.2025
- News
Why Veterans With PTSD Are Turning to Psychedelics
Veterans are increasingly exploring psychedelic treatments—like ketamine, ayahuasca, psilocybin, MDMA, and ibogaine—to heal from PTSD. These therapies tend to be used in guided, clinically-informed settings, with some programs even including spouses for shared healing. Although ibogaine remains illegal in the U.S., many veterans are traveling abroad, driven by promising early results
- 7.2.2025
- News
‘Psychedelics and the Texas Trip’ explores science & history behind state-funded research initiative
Texas recently approved $50 million in public funding, matched privately, to study ibogaine—a plant-derived psychedelic—as a potential treatment for PTSD, TBI, addiction, and related conditions. The initiative is facilitated through a public–private partnership and includes protections to ensure future therapy revenues fund veterans’ programs
- 7.2.2025
- News
Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing
Texas is the first state to fund clinical trials of ibogaine, investing $50 million in public funds to explore its potential for treating PTSD, addiction, and TBI—with future revenues supporting veterans’ programs.